Price caps on drugs helped patients save Rs 11.5k cr: Government

Mumbai: Price caps on 856 essential medicines fixed by the National Pharmaceutical Pricing Authority (NPPA) have resulted in savings of Rs 11,462 crore for patients, said minister of state for chemicals and fertilizers Mansukh L Mandaviya. While giving a written reply in the Lok Sabha, he stated that no shortage in coronary stents was reported after their ceiling prices were fixed last year.

At present, prices have been fixed for 856 formulations, including four medical devices, which are covered under Schedule–I of the Drug Price Control Orders (DPCO), 2013.

According to paragraph 20 of the DPCO, the NPPA monitors the maximum retail prices (MRPs) of all drugs, including the non-scheduled formulations, and ensures no manufacturer can increase it over 10% of the MRP in preceding twelve months.

The department of pharmaceuticals has also launched ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)’ in order to make quality generic medicines at affordable prices through specific outlets. As of date, 4,571 PMBJP outlets are functional across the country, Mandaviya said.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert